TCGA-AQ-A7U7-01A-22R-A352-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.650
- ALLOGRAFT_REJECTION+0.540
- IL6_JAK_STAT3_SIGNALING+0.490
- INFLAMMATORY_RESPONSE+0.450
- TNFA_SIGNALING_VIA_NFKB+0.410
- COMPLEMENT+0.340
- IL2_STAT5_SIGNALING+0.320
- WNT_BETA_CATENIN_SIGNALING+0.320
- KRAS_SIGNALING_UP+0.310
Top 10 suppressed
- MYC_TARGETS_V1-0.670
- MYC_TARGETS_V2-0.630
- OXIDATIVE_PHOSPHORYLATION-0.620
- E2F_TARGETS-0.570
- MTORC1_SIGNALING-0.530
- ADIPOGENESIS-0.520
- G2M_CHECKPOINT-0.510
- PROTEIN_SECRETION-0.480
- FATTY_ACID_METABOLISM-0.470
- ANDROGEN_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X0e8b5ba7.3bee.4627.a8b6.f94263f78e3e | — | cohortMD2 | 0.950 |
| 2 | TCGA-93-A4JQ-01A-11R-A24X-07 | — | cohortA1 | 0.938 |
| 3 | SRR2774280 | — | — | 0.934 |
| 4 | 767fc312-2c66-43f7-b78e-bf79e03e3a0a | — | — | 0.927 |
| 5 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.922 |
| 6 | SRR8613789 | — | A | 0.917 |
| 7 | AUR-AE6X-TTP1-A-1-0-R-A741-41 | — | D | 0.916 |
| 8 | TCGA-C8-A8HR-01A-11R-A36F-07 | — | A | 0.916 |
| 9 | DRR168577 | — | — | 0.914 |
| 10 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.913 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.650 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |